Platelet GPIIb/IIIa binding characteristics of small molecule RGD mimetic: distinct binding profile for Roxifiban
Authors:
- 1 June 2001
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 133 (3) , 331-336
Abstract
A number of non‐peptide orally active RGD mimetic prodrug such as Orbofiban, Sibrafiban, SR121566, Roxifiban and others entered into the clinical evaluation stage. Some of these agents were terminated and some are still in clinical trials. The present study examined the platelet GPIIb/IIIa binding profiles for the active form of Roxifiban, Sibrafiban, SR121566 and Orbofiban using 3H‐Roxifiban active form (XV459), 3H‐DMP728, 125I‐Echistatin, and 125I‐Fibrinogen. Either DMP728, Orbofiban, Sibrafiban, SR121566 or Roxifiban active form as well as other RGD mimetic bind to the same binding site (s) on human platelets as evident from the competitive inhibition of binding of each other to human platelet. Additionally, Roxifiban active form competed with FITC labeled GPIIb/IIIa antagonist cyclic RGD peptidomimetic (XL086) as demonstrated using confocal microscopy technique. Roxifiban active form (XV459) demonstrated the highest potency in inhibiting 3H‐XV459, 3H‐DMP728, 125I‐Echistatin, and 125I‐Fibrinogen binding to human platelets as compared to the others. Structure activity relationship within the isoxazoline Roxifiban series showed that substituent at the α‐carbon next to the carboxy terminal represents an exosite for the affinity binding to human platelets leading to slow platelet dissociation rate. These data indicated a distinct binding profile for Roxifiban (high affinity to both activated and resting platelets associated with a relatively slow Koff) as compared to others. These differences might determine the pharmacodynamics and pharmackokinetics of the different GPIIb/IIIa antagonists. British Journal of Pharmacology (2001) 133, 331–336; doi:10.1038/sj.bjp.0703943Keywords
This publication has 34 references indexed in Scilit:
- Orally Active Isoxazoline Glycoprotein IIb/IIIa Antagonists with Extended Duration of ActionJournal of Medicinal Chemistry, 1999
- XV454, a Novel Nonpeptide Small-Molecule Platelet GIIb/IIIa Antagonist with Comparable Platelet αIIbβ3-Binding Kinetics to c7E3Journal of Cardiovascular Pharmacology, 1998
- Orally Active Isoxazoline GPIIb/IIIa AntagonistsCardiovascular Drug Reviews, 1998
- Discovery of an Orally Active Series of Isoxazoline Glycoprotein IIb/IIIa AntagonistsJournal of Medicinal Chemistry, 1997
- Discovery of Potent Isoxazoline Glycoprotein IIb/IIIa Receptor AntagonistsJournal of Medicinal Chemistry, 1997
- Novel nonpeptide antiplatelet glycoprotein llb/llla receptor antagonist, DMP754Coronary Artery Disease, 1996
- Novel antithrombotic approaches to coronary artery diseaseThe American Journal of Cardiology, 1995
- Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six monthsThe Lancet, 1994
- Platelet Membrane Glycoprotein IIb/IIIa: Member of a Family of Arg-Gly-Asp—Specific Adhesion ReceptorsScience, 1986
- Exposure of platelet fibrinogen receptors by ADP and epinephrine.Journal of Clinical Investigation, 1979